ORIONS Money Stocks

[~ Blue ~]

AEZS's cancer drug founder has Nobel Prize in Medicine

1) Zoptarelin doxorubicin was developed by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami.

The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer and endometrial cancer.

https://en.wikipedia.org/wiki/Zoptarelin_doxorubicin


About Andrew Schally


https://en.wikipedia.org/wiki/Andrew_Schally

2) AEZS~ August 25, NEW presentation!

http://www.aezsinc.com/pdfdyn/AEZS%20Presentation%20AUG_25-2015-FINAL.pdf

3) AEZS fact sheet august 2015

http://www.aezsinc.com/pdfdyn/FACT-SHEET-ENG-August-2015%20Final.pdf


4) AEZS~ huge success in Prostate Cancer trial!

A phase I trial in prostate cancer indicated that nine out ten evaluable patients achieved disease stabilization through administration of zoptarelin doxorubicin.


https://en.wikipedia.org/wiki/Zoptarelin_doxorubicin

http://clincancerres.aacrjournals.org/content/20/24/6277